Amgen, Xencor partner to build up and commercialize new therapeutics for cancer immunotherapy, inflammation Amgen and Xencor, Inc customers-reviews.html . announced today that both companies have entered right into a analysis and license contract to develop and commercialize novel therapeutics in the areas of tumor immunotherapy and swelling. The collaboration contains molecular engineering by Xencor and the preclinical advancement of bispecific molecules for five applications proposed by Amgen, leveraging XmAb bispecific Fc domains to make half-life extended T cell engagers and dual targeting bispecific antibodies.
and reMYND NV today announced the signing of a partnership agreement to own Amorfix A4 amyloid testing service to reMYND’s agreement research clients. ReMYND’s contract research business offers an considerable portfolio of preclinical in-vivo efficacy, pharmacokinetic and security examining of experimental Alzheimer therapies using proprietary mouse models of Alzheimer’s disease . ‘We are pleased to be dealing with reMYND to provide our A4 services to their clients, collectively providing a comprehensive alternative to assess efficacy of medication candidates for treating AD using their proprietary models,’ stated Vigen Nazarian, Vice President of Strategic Alliances for Amorfix. ‘This partnership can be an important first step to accessing new clients as we build our AD services business.